Potential Indications for factor XII– or factor XI–directed strategies
| Indication . | Rationale . |
|---|---|
| Primary VTE prophylaxis | Long-acting strategies such as antisense oligonucleotides or antibodies permit simple and safe single-dose regimens for extended thromboprophylaxis in medically ill patients or after major orthopedic surgery |
| Secondary VTE prophylaxis | May be safer than current therapies for secondary prevention in patients with unprovoked or cancer-associated venous thromboembolism |
| Prevention of recurrent ischemia after ACS | May provide a safer anticoagulant platform on top of single- or dual-antiplatelet therapy |
| End-stage renal disease | May be safe and effective for reducing cardiovascular death, myocardial infarction, and stroke in patients receiving hemodialysis |
| High-risk atrial fibrillation patients | May be safer than current therapies for stroke prevention in patients with atrial fibrillation at high risk of bleeding such as those with a history of major bleeding or with end-stage renal disease |
| Medical devices | May be more effective and safer than current therapies to prevent clotting on mechanical heart valves, left ventricular assist devices, small caliber grafts, or central venous catheters |
| Extracorporeal circuits | May be more effective and safer than heparin to prevent clotting on extracorporeal membrane oxygenator or cardiopulmonary bypass circuits |
| Indication . | Rationale . |
|---|---|
| Primary VTE prophylaxis | Long-acting strategies such as antisense oligonucleotides or antibodies permit simple and safe single-dose regimens for extended thromboprophylaxis in medically ill patients or after major orthopedic surgery |
| Secondary VTE prophylaxis | May be safer than current therapies for secondary prevention in patients with unprovoked or cancer-associated venous thromboembolism |
| Prevention of recurrent ischemia after ACS | May provide a safer anticoagulant platform on top of single- or dual-antiplatelet therapy |
| End-stage renal disease | May be safe and effective for reducing cardiovascular death, myocardial infarction, and stroke in patients receiving hemodialysis |
| High-risk atrial fibrillation patients | May be safer than current therapies for stroke prevention in patients with atrial fibrillation at high risk of bleeding such as those with a history of major bleeding or with end-stage renal disease |
| Medical devices | May be more effective and safer than current therapies to prevent clotting on mechanical heart valves, left ventricular assist devices, small caliber grafts, or central venous catheters |
| Extracorporeal circuits | May be more effective and safer than heparin to prevent clotting on extracorporeal membrane oxygenator or cardiopulmonary bypass circuits |